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ABSTRACT: Phosphorous containing chitosan (PCTS) was synthesized by a
graft copolymerization technique in order to be used as controlled drug deliv-
ery devices. To test this potential, PCTS beads were prepared by using
tripolyphosphate, at pH 4.0 and characterized by scanning electron
microscopy. The in vitro drug release behavior in various pH solutions was
studied using indomethacin (IM) as a model drug at two different concentra-
tions (0.3 and 0.6% w/w). The release percent of IM from PCTS beads was
found to be increased with the increasing of pH in the buffer solution. The
release rate of IM at pH 7.4 was higher than that at pH 1.4, due to the ioniza-
tion of phosphorous groups and the high solubility of IM in the alkaline
medium. These results indicated that PCTS beads have the potential to be
used as controlled drug delivery systems through oral administration by avoid-
ing the drug release in the highly acidic gastric fluid region of the stomach.
KEY WORDS: modified chitosan, chitosan beads, indomethacin, drug deliv-
ery, pH sensitive drug delivery, oral drug delivery.
INTRODUCTION
Chitosan (CS) is a biopolymer comprised of D-glucosamine and D-acetyl-glucosamine units that can be readily processed into
films, porous scaffold, beads and fibers from aqueous acid solution. CS
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beads have been developed for controlled drug release and removal of
heavy metal ions from waste water [1–3]. CS displays interesting prop-
erties such as biocompatibility, biodegradability [4] and its degradation
products are non-toxic, non-immunogenic and non-carcinogenic [5].
Recently, there has been a growing interest in studying the chemical
modification of CS to improve its solubility and widen its applications
[6–10]. Among the various methods, graft copolymerization is the most
attractive because it is a useful technique for modifying chemical and
physical properties of natural polymers. CS has both primary amine
and alcohol reactive groups that can be grafted. Covalent grafting of
molecule entities allows the formation of functional derivatives onto
CS backbone with desired chemical groups. It has been shown that,
after primary deviation followed by graft modification, CS improved
water solubility and bioactivities such as antibacterial and antioxidant
properties [11–13], chelating [14] or complexation properties [15], bac-
teriostatic effect [16] or enhancing adsorption properties [17,18].
Although the grafting of CS modifies its properties, it is possible to
maintain some interesting characteristics such as mucoadhesivity [19],
biocompatibility [20–22] and biodegradability [23]. Many investiga-
tions have been carried out on the graft copolymerization of CS
[13–22] with a view to preparing polysaccharide-based advanced
materials with unique properties and thus widening their applications
in biomedical and environmental fields.
CS is a very promising biomaterial for drug delivery as it readily
responds to pH. However, the use of soluble CS polymer in oral admin-
istration is restricted by its fast dissolution in the stomach and limited
capacity for a controlled drug delivery system [24]. In order to over-
come these disadvantages, tripolyphosphate (TPP)/CS polyelectrolyte
complexes as gel beads were developed for sustained release perfor-
mances [25–28]. PCTS has attracted considerable interest because
among its advantages, it exhibits anti-inflammatory properties and it
forms both metal complexes and anionic polyelectrolyte hydrogels
[29–33]. In this work, CS was grafted with TPP to prepare beads in
order to improve the sustained release system in a gastric fluid. By
using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) mediated
coupling reaction, 2-carboxethyl phosphonic acid was covalently
grafted onto chitosan. The morphology, swelling properties and in
vitro drug profiles of the prepared beads were evaluated to obtain an
insight to the potential of this system for pH sensitive controlled
release of drugs or other bioactive molecules.
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EXPERIMENTAL
Materials
Chitosan (CS) (deacetylation degree 75–85%), tripolyphosphate
(TPP) and 2-carboxyethylphosphonic acid were purchased from
Aldrich. EDC was obtained from Alfa Aesar Company. IM was pur-
chased from Fluka. All other materials used were of analytical grade.
Synthesis of Phosphorous Containing Chitosan (PCTS)
PCTS was prepared according to the method reported in [32].
Briefly, CS (0.9712 g) was dissolved in 10 mL of 1% w/w acetic
acid/methanol solution and the pH solution was then raised to 5.5 by
adding 1M NaOH. 2-Carboxyethylphosphonic acid (0.4621 g) was dis-
solved in 10 mL of water and then added drop by dropwise to the CS
solution. To this mixture EDC (0.4552 g) was added. The reaction was
carried out at 70°C for 7 h. The reaction mixture was filtered and
affluent dialyzed against spectropor membrane tubing (Mw cut-off
3500) for 3 days with 10 changes of water to eliminate the impurities.
The resulting solution was precipitated with acetone and dried at
room temperature.
Preparation of Phosphorous Containing Chitosan (PCTS)
Beads
PCTS beads were prepared using an ionotropic gelation process
with the counter polyanion TPP. PCTS (0.7512g) was dissolved in
10mL of 2% w/w acetic acid solution and stirred for 24h to obtain a
transparent homogeneous solution. The PCTS solution with or
without drug was introduced into a stirred 10% TPP aqueous phase
using a syringe needle (0.5mm in diameter); solid white beads were
formed immediately. These beads were allowed to stand for 1h in the
TPP solution with occasional agitation at room temperature and pH
4.0. The gel beads were filtered, washed with distilled water repeatedly
and dried under vacuum at room temperature for 2 days. For the
preparation of drug loaded PCTS beads, two different amounts of IM
(0.3 and 0.6% w/w with respect to PCTS solution) were dispersed in
10mL of PCTS solution for 24h. The same procedure was followed for
the isolation and purification as described above.
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Swelling Evaluation
The dried CS and PCTS beads were carefully weighed and immersed
in to 50mL of buffer solutions of pH 1.4 and 7.4 at 37°C. At predeter-
mined time intervals, swollen beads were taken out, and the excess
water was blotted with filter paper from the surface, and then weighed.
The following equation was used to determine the swelling degree:
Swelling degree [%]!{(Xw"Xd)/Xd}#100 (1)
where Xd and Xw represent the mass of dry and swollen beads, respec-
tively.
Determination of Drug Loading Efficiency
During the gelation process in TPP aqueous solution, some IM dif-
fused from PCTS droplet into TPP solution. After gelation, the IM con-
centration in the TPP solution was determined by a UV
spectrophotometer at 320nm. The loading efficiency during the gela-
tion process was calculated by the following formula:
Loading efficiency [%]!{(m"c#v)/m}#100 (2)
where m, c and v represent the initial IM mass in PCTS droplet, the
IM concentrations in TPP solution and the volume of TPP solution,
respectively.
In Vitro Drug Release Studies
In vitro release tests were carried out on all formulations of the
drug-loaded CS beads and PCTS beads. Known amounts of drug-
loaded gel beads were suspended in 100 mL of various buffer solu-
tions in different pH media (1.4, 5.8, 7.4 and 9.4, respectively),
stirred at 120 rpm and maintained at 37°C in a water bath. At prede-
termined time intervals, 1 mL aliquots were withdrawn and dilu-
tioned to determine the concentration of drug released by UV
spectrophotometry at 320 nm. The dissolution medium was replaced
with a fresh buffer to maintain the total volume. The drug release
percent was determined in terms of percentage by the following
equation:
Drug release [%]!Rt/L#100 (3)
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where, L and Rt represent the initial amount of drug loaded and the
cumulative amount of drug released at time t.
Characterization Studies
The surface morphology of samples was analyzed by scanning elec-
tron microscopy (Leica Canbridge S360 microscope). The drug release
was monitored by UV spectrophotometry (Shimadzu UV-1601, Japan).
The IR spectrum was recorded with a double-beam Perkin-Elmer 1600
FTIR spectrophotometer.
RESULTS AND DISCUSSION
Synthesis of Phosphorous Containing Chitosan (PCTS) Beads
Chitosan (CS, a polycationic polysaccharide) forms gels with multi-
valent counter ions through the formation of intermolecular or intra-
molecular linkages by ionic interactions. The liquid-gel transition of
PCTS in TPP aqueous solution is due to the electrostatic interactions
between positively charged free amino groups with negatively charged
counter anion TPP [24]. A structure of PCTS beads is shown in Figure 1.
The small molecule polyelectrolyte TPP dissociated in water and
released OH" ions, thus providing both OH" and P3O105" ions which
coexisted in the TPP solution. The OH" and P3O105" ions could ioni-
cally react with the —NH3$ binding site on PCTS by deprotonation
and crosslinking, respectively. The CS-TPP complex formation in the
gel beads was less time dependant when the outer layer was formed.
The CS-phosphoric acid complexation gel beads were found to be time
dependant [34]. Consequently, for the PCTS beads, the electrostatic
attraction would be dependant on the residual —NH2.
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Figure 1. Structure of PCTS.
SEM of Beads
The SEM of the CS and PCTS beads is shown in Figure 2; based on
these SEM images the size of the CS and PCTS beads varied from 1.5
to 1.75mm. The CS beads exhibited a smooth surface morphology as
well as a more regular spherical geometry and smooth surface than the
PCTS beads. This may be due to a more efficient crosslinking in the CS
beads. The PCTS beads exhibited some fissures on the surface that
may be due to the grafting of phosphorous containing monomer.
Crosslinking of PCTS beads was less efficient; some of the amino
groups of CS were substituted by phosphorous which led to the forma-
tion of a rougher and non-uniform surface structure.
Swelling Behavior of Beads
The swelling behavior of the CS and PCTS beads in pH 1.4 and 7.4
solutions at 37°C are shown in Figures 3 and 4. The PCTS beads at pH
1.4 disintegrated within 3 days and then dissolved while the CS beads
dissolved after 4 days. These results showed that the swelling of the
CS-TPP beads was different from that of PCTS beads agreement with
the difference in their crosslinking density. The less crosslinked PCTS
beads swelled quickly and gradually dissolved within 3 days, whereas
the highly crosslinked CS beads did not dissolve within the same time
period. This was expected behavior, due to the high amount of inter-
chain linkages and masking of the hydrophilic nature of the amino
groups in the high ionic crosslinked CS-TPP network [35]. The
swelling percentage was found to be much higher at pH 1.4 than pH
7.4. Moreover, the swelling reached a stable equilibrium more rapidly
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Figure 2. SEM of the beads (a) CS and (b) PCTS. Scale bars = 1mm
(a) (b)
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Figure 3. Swelling behavior of the CS and the PCTS beads at pH 1.4.
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Figure 4. Swelling behavior of the CS and the PCTS beads at pH 7.4.
at pH 7.4 than at pH 1.4. This was due to the lack of protonation of
amino groups at pH 7.4, which prevents swelling in an alkaline
medium [36].
Entrapment of IM in PCTS Beads
IM is a non-steroid anti-inflammatory drug used for the treatment
of arthritis [33]. It was efficiently entrapped into both CS and PCTS
beads during the ionotropic process (Table 1). The relatively high effi-
ciency of loading may be due to the low water-solubility of IM as well
as the ionic binding between negatively charged carboxyl groups in IM
and positively charged free amino groups in CS. The carboxyl groups
in IM and the phosphorous groups in PCTS are ionized at pH 4. In this
work, the drug was not chemically attached to the polymer. Thus, the
drug in the gel was only held by the electrostatic and hydrophobic
interactions, and physical entrapment within the polymer matrix. Con-
sequently, the drug remained in a biologically active form and thera-
peutically effective in the body as soon as it was released from the
polymeric matrix.
The In Vitro Release Profiles of IM
The release profiles for 0.3% IM-PCTS beads at various pH’s and at
37°C in a buffer solution are shown in Figure 5. In general, the percent
of drug released increased with increasing pH of medium. Within 3h,
30% of the IM was released from the PCTS beads at pH 1.4 and 50% at
pH 7.4. This behavior indicates that drug release profiles are pH-sensi-
tive. There are two factors to be considered in the noticeably higher
release rate of IM at pH 7.4 than at pH 1.4. The first factor is the high
solubility of IM in alkaline medium and the other is the electrostatic
repulsion between the negatively ionized carboxyl group of IM and the
phosphate groups in PCTS at pH 7.4 [36–38]. Similar drug release pro-
files were observed for the CS beads. However, the release percentage
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Table 1. Loading efficiencies for IM-loaded CS and PCTS beads.
Initial Drug Content Loading Level Loading Efficiency 
Formulation (mg/g-beads) (mg/g-beads) (%)
0.3% IM-CS 28.9 27.11%0.5 93.81%1.9
0.6% IM-CS 58.2 53.21%2.0 91.43%3.8
0.3% IM-PCTS 28.9 25.17%0.3 87.09%1.4
0.6%IM-PCTS 58.2 49.34%5.1 84.78%5.3
of IM at pH 1.4 was found to be less than that for the PCTS beads. The
reason may be due to the formation of complexes between the carboxyl
group of IM and the amino group of CS and poor solubility of the drug
at pH 1.4 [36–38]. The diffusion rate of the drug molecules was higher
in the alkaline medium, effectively contributing to the controlled drug
release. The polymer matrix probably combines two types of mechan-
isms for drug release: controlled diffusion and swelling. The in vitro
release profiles of 0.6% IM-loaded CS and PCTS beads at pH 1.4 and
7.4 are shown in Figure 6; similar release profiles were observed.
The influence of the initial drug loading on the release profiles of IM
from PCTS beads at pH 1.4 and 7.4 is shown in Figure 7. Surprisingly,
there was no significant difference between the release of IM for 0.3
and 0.6% loaded PCTS beads. For initial drug loadings, the amounts of
IM released per unit mass of PCTS beads at pH 7.4, are shown in
Figure 8. As expected, the amount of drug released from highly loaded
beads was higher than that from slightly loaded beads. Increasing the
initial drug content provided the larger equilibrium amount of drug
released at each pH.
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Figure 5. Release profiles of IM from 0.3% loaded PCTS beads in various pH media.
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Figure 6. Drug release from IM-loaded PCTS beads with different initial drug contents
(0.3 and 0.6%) in simulated gastric fluid, pH 1.4, and simulated intestinal fluid, pH 7.4.
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CONCLUSIONS
In this work, PCTS beads were developed in order to be used as a
pH sensitive and gastric fluid-resistant drug carriers. The beads were
prepared under mild conditions at room temperature and pH 4.0, and
the loading efficiency of the model drug, IM, was over 85%. The water
solubility of the drug, the swelling degrees of beads and the ionization
of phosphate groups were found to have a significant influence on the
release profiles of IM at various pHs. For example, the release rate
from the PCTS beads in simulated intestinal fluid (pH 7.4) was higher
than that in simulated gastric fluid (pH 1.4). These factors suggest
that the PCTS beads could be better than chitosan beads as a con-
trolled drug delivery system for oral administration by avoiding drug
release in the highly acidic gastric fluid region of the stomach.
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